GPR6 and Alzheimer disease: Gpr6 is an adenylate cyclase-activating GPCR (Gs) with CBD as an inverse agonist and has been proposed as a therapeutic target of AD and Parkinson's disease (Laun et al., 2019; Benoit et al., 2013).